Guardant Health, Inc. has disclosed a recent stock transaction involving its director, Alex M. Azar II. On October 12, 2026, Azar acquired 137 shares of common stock and an additional 137 restricted stock units. This transaction is significant as it highlights ongoing changes in ownership within the company.
Guardant Health, based in Palo Alto, California, operates in the medical laboratory services sector, classified under SIC 8071. The company trades on the Nasdaq under the ticker symbol GH. As a large accelerated filer, Guardant Health is subject to specific reporting requirements, ensuring transparency in its operations and transactions.
According to the SEC filing, the acquisition of shares by Azar is a direct ownership transaction, meaning he now holds a total of 962 shares following this transaction. The restricted stock units acquired will vest over a four-year period, with 25% vested on September 12, 2026, and the remaining shares vesting monthly thereafter.
This update may impact various stakeholders, including investors and analysts monitoring Guardant Health's executive ownership changes. The medical laboratory services industry is characterized by active trading among executives, which can influence market sentiment and investor confidence.
The filing does not specify what happens next regarding further transactions or additional disclosures. However, Guardant Health's ongoing commitment to transparency is evident in its recent filings, which demonstrate an effort to keep shareholders informed about significant changes in ownership.